商务合作
动脉网APP
可切换为仅中文
Approval of YONDELIS
YONDELIS 的批准
®
®
(trabectedin) by the Thai FDA for patients who have failed prior treatment with anthracyclines and ifosfamide or for those who are unsuited to receive these agents
(曲贝替定)获泰国食品药品监督管理局批准,用于既往蒽环类药物和异环磷酰胺治疗失败的患者,或不适于接受这些药物治疗的患者。
1
1
YONDELIS provides an additional treatment option for Thai adults diagnosed with advanced soft tissue sarcoma
YONDELIS 为确诊为晚期软组织肉瘤的泰国成人患者提供了额外的治疗选择
Eligible adult patients in Thailand with advanced soft tissue sarcoma will have access to YONDELIS from 1
泰国符合条件的晚期软组织肉瘤成年患者将可获得YONDELIS
st
第一
December 2026
2026年12月
SINGAPORE
新加坡
,
,
Nov. 15, 2026
2026年11月15日
/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics
/美通社/ -- 独立生物制药公司 Specialised Therapeutics
announced
宣布
that the Thailand Food and Drug Administration approved YONDELIS
泰国食品药品监督管理局批准了YONDELIS
®
®
(trabectedin) on 24 July 2026 for the treatment of adult patients with advanced soft tissue sarcoma (STS).
(曲贝替定)于2026年7月24日获批用于治疗晚期软组织肉瘤(STS)成年患者。
1
1
The regulatory approval grants access to YONDELIS for patients who have failed prior treatment with anthracyclines and ifosfamide, or for those who are unsuited to receive these agents.
该监管批准使得YONDELIS可用于既往蒽环类药物和异环磷酰胺治疗失败的患者,或不适于接受这些药物治疗的患者。
1
1
The approval is based on the clinical efficacy and safety data from the Phase 3, randomized, open-label, controlled study (ET743-SAR-3007), which evaluated YONDELIS versus the chemotherapy agent dacarbazine in patients with unresectable or metastatic liposarcoma or leiomyosarcoma previously treated with an anthracycline and at least one additional chemotherapy regimen..
该批准基于III期随机、开放标签、对照研究(ET743-SAR-3007)的临床疗效和安全性数据,该研究评估了YONDELIS与化疗药物达卡巴嗪在既往接受过蒽环类药物及至少一种额外化疗方案治疗的不可切除或转移性脂肪肉瘤或平滑肌肉瘤患者中的疗效。
2,3
2,3
In the pivotal Phase 3 clinical trial, patients treated with YONDELIS achieved a statistically significant improvement in median progression-free survival (PFS) of 4.2 months versus 1.5 months for trabectedin vs dacarbazine HR, 0.55;
在关键的III期临床试验中,接受YONDELIS治疗的患者中位无进展生存期(PFS)达到4.2个月,而达卡巴嗪组为1.5个月,差异具有统计学意义(曲贝替定对比达卡巴嗪的风险比[HR]为0.55);
p
p
<0.001, representing a 45% reduction in the risk of disease progression or death.
<0.001,代表疾病进展或死亡风险降低45%。
2
2
YONDELIS demonstrated a manageable safety profile, with severe (Grade 3 or 4) adverse reactions occurring in less than one-third of patients. The most common adverse reactions of any severity grade included neutropenia, nausea, vomiting, elevated liver enzymes (AST/ALT), anaemia, fatigue, thrombocytopenia, decreased appetite, and diarrhoea..
YONDELIS 显示出可控的安全性特征,严重(3 级或 4 级)不良反应发生在不到三分之一的患者中。任何严重程度的最常见不良反应包括中性粒细胞减少、恶心、呕吐、肝酶升高(AST/ALT)、贫血、疲劳、血小板减少、食欲下降和腹泻。
1,2
1,2
YONDELIS is an established antineoplastic agent originally derived from the sea squirt (
YONDELIS 是一种成熟的抗肿瘤药物,最初源自海鞘(
Ecteinascidia turbinata
海鞘
). It exerts the anti-tumor effect by binding to the minor groove of DNA, disrupting the cell cycle and preventing cancer cells from multiplying.
)。它通过与DNA的小沟结合,扰乱细胞周期并阻止癌细胞增殖,从而发挥抗肿瘤作用。
4
4
STS is a rare and complex disease. In Thailand, the age-standardized incidence rate of STS is 2.14 per 100,000 person-years, which is relatively low compared to Western nations. The most frequently reported histological subtypes among Thai patients are unspecified sarcoma (24.8%), leiomyosarcoma (19.0%), and liposarcoma (11.4%).
软组织肉瘤(STS)是一种罕见且复杂的疾病。在泰国,STS的年龄标准化发病率为每10万人年2.14例,与西方国家相比相对较低。泰国患者中最常报道的组织学亚型为未分化肉瘤(24.8%)、平滑肌肉瘤(19.0%)和脂肪肉瘤(11.4%)。
While current healthcare treatments yield a five-year relative survival rate of 62.6% for soft tissue sarcoma in Thailand, there remains a critical need for advanced, specialised therapies for patients whose cancer progresses or relapses after initial care..
尽管泰国目前的医疗手段使软组织肉瘤患者的五年相对生存率达到62.6%,但对于在初始治疗后癌症进展或复发的患者,仍然迫切需要更先进、更专业的治疗方案。
5
5
Carlo Montagner, CEO, Specialised Therapeutics, commented:
Specialised Therapeutics 首席执行官 Carlo Montagner 表示:
'The approval of YONDELIS in Thailand expands access to a recognized, international standard-of-care therapy for patients living with advanced STS. STS remains a complex disease with limited treatment options once initial therapies fail. Securing regulatory approval in Thailand aligns with our core mission to address unmet medical needs and deliver specialised oncology therapies across South East Asia.'.
“YONDELIS在泰国的获批,为晚期软组织肉瘤(STS)患者扩大了获得国际公认标准治疗的机会。STS仍是一种复杂的疾病,在初始治疗失败后选择有限。在泰国获得监管批准符合我们的核心使命,即解决未满足的医疗需求,并在东南亚地区提供专业化的肿瘤治疗药物。”
Under an exclusive licensing agreement with global partner PharmaMar S.A., Specialised Therapeutics will be responsible for all regulatory, commercialisation, distribution, and medical engagement operations for YONDELIS in Thailand.
根据与全球合作伙伴 PharmaMar S.A. 签订的独家许可协议,Specialised Therapeutics 将负责 YONDELIS 在泰国的所有监管、商业化、分销及医学事务运营。
About Specialised Therapeutics
关于 Specialised Therapeutics
Specialised Therapeutics (ST) is an international biopharmaceutical company dedicated to commercializing novel, high-value therapies and diagnostic technologies across Australia, New Zealand, and South East Asia. ST collaborates with leading global biopharmaceutical partners to deliver healthcare solutions where there is an unmet clinical need.
Specialised Therapeutics(ST)是一家国际生物制药公司,致力于在澳大利亚、新西兰和东南亚地区商业化创新且高价值的疗法及诊断技术。ST与全球领先的生物制药合作伙伴携手,为满足尚未被满足的临床需求提供医疗解决方案。
For additional information, visit .
如需更多信息,请访问。
www.stbiopharma.com
www.stbiopharma.com
.
。
About PharmaMar
关于 PharmaMar
Headquartered in Spain, PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them.
PharmaMar 是一家总部位于西班牙的生物制药公司,专注于新型肿瘤治疗药物的研发,其使命是通过创新药物改善患有严重疾病患者的医疗效果。公司灵感源于海洋,以科学为驱动,并以服务重症患者为己任,通过提供新颖药物来改善他们的生活。
PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation..
PharmaMar 旨在继续保持其在全球海洋药物发现、开发和创新领域的领先地位。
For more information, please visit:
更多信息,请访问:
www.pharmamar.com
www.pharmamar.com
About YONDELIS
关于 YONDELIS
®
®
(trabectedin)
(曲贝替定)
Yondelis
Yondelis
®
®
(trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis
(曲贝替定)是一种新型合成抗肿瘤药物,最初从一种名为Ecteinascidia turbinata的海鞘中分离得到。Yondelis
®
®
exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.
其抗癌作用主要通过抑制活跃转录来实现,而增殖中的癌细胞特别依赖于这种基因表达形式。
6
6
Important Safety Information on YONDELIS
YONDELIS 的重要安全信息
YONDELIS is contraindicated in patients with concurrent serious or uncontrolled infections. Patients who develop a fever should promptly seek medical attention so active supportive therapy can be started immediately. Women of childbearing potential must use highly effective contraception during treatment and 8 months thereafter and immediately inform the treating physician if a pregnancy occurs.
YONDELIS 禁用于伴有严重或未控制感染的患者。出现发热的患者应立即就医,以便即刻开始积极的支持治疗。具有生育潜力的女性在治疗期间及治疗后8个月内必须采取高效避孕措施,若发生妊娠,应立即告知主治医生。
Men of fertile age must use highly effective contraception during treatment and 5 months after treatment..
育龄男性在治疗期间及治疗后5个月内必须采取高效避孕措施。
1,2
1,2
In clinical trials, the most common adverse reactions of any severity grade were neutropenia, nausea, vomiting, increased liver enzymes (AST/ALT), anaemia, fatigue, thrombocytopenia, anorexia, and diarrhoea. Less than one-third of patients experienced serious adverse reactions of Grade 3 or 4 severity.
在临床试验中,任何严重程度的最常见不良反应包括中性粒细胞减少、恶心、呕吐、肝酶(AST/ALT)升高、贫血、疲劳、血小板减少、厌食和腹泻。不到三分之一的患者出现了3级或4级严重不良反应。
Fatal adverse reactions occurred in 1.9% of patients and were often the result of combined events including pancytopenia, febrile neutropenia, sepsis, hepatic involvement, multiorgan failure, and rhabdomyolysis..
1.9%的患者发生了致命性不良反应,这些反应通常是包括全血细胞减少、发热性中性粒细胞减少、脓毒症、肝脏受累、多器官衰竭和横纹肌溶解在内的复合事件所致。
2
2
Treatment with YONDELIS can cause severe myelosuppression, including Grade 3 or 4 neutropenia and thrombocytopenia. A full blood cell count including differential and platelet count must be performed at baseline, weekly for the first two cycles, and then once between cycles. Liver function tests and creatinine clearance must also be closely monitored prior to and during treatment to manage the risks of hepatotoxicity and renal impairment..
YONDELIS 治疗可能导致严重的骨髓抑制,包括 3 级或 4 级中性粒细胞减少症和血小板减少症。必须在基线时、前两个疗程每周以及随后各疗程之间进行一次全血细胞计数(包括分类计数和血小板计数)。此外,在治疗前和治疗期间必须密切监测肝功能检查和肌酐清除率,以管理肝毒性和肾功能损害的风险。
YONDELIS is a prescription medicine and can only be prescribed by a doctor. For more information about YONDELIS, or advanced STS, please see your health care professional.
YONDELIS 是一种处方药,只能由医生开具。如需了解有关 YONDELIS 或晚期软组织肉瘤(STS)的更多信息,请咨询您的医疗保健专业人员。
References
参考文献
1. YONDELIS
1. 优尼得利斯
®
®
(trabectedin) Thai FDA Product Information. (
(曲贝替定)泰国食品药品监督管理局产品信息。(
Link
链接
)
)
2. Demetri GD, von Mehren M, Jones RL, et al.
2. Demetri GD, von Mehren M, Jones RL, 等.
J Clin Oncol.
《临床肿瘤学杂志》
2016; 34(8):786-793.
2016;34(8):786-793。
3. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma. Version 5.2026
3. NCCN肿瘤学临床实践指南。软组织肉瘤。2026年第5版
4. D'Incalci M, Galmarini CM.
4. D'Incalci M,Galmarini CM。
Mol Cancer Thera
分子癌症治疗学
2010; 9(8): 2157-2163.
2010;9(8):2157-2163。
5. Klangjorhor J, Pongnikorn D, Sittiju P et al.
5. Klangjorhor J, Pongnikorn D, Sittiju P 等
Scientific Reports
《科学报告》
2022; 12:12824
2022; 12:12824
6. Brodowicz T. Trabectedin in Soft Tissue Sarcoma. Future Oncol. 2014; 10(8):1–5
6. Brodowicz T. 曲贝替定在软组织肉瘤中的应用. 《未来肿瘤学》. 2014; 10(8):1–5
SOURCE Specialised Therapeutics
来源:Specialised Therapeutics